Eli Lilly and Company (LLY)vsPACS Group, Inc. (PACS)
LLY
Eli Lilly and Company
$1,354.49
-0.79%
HEALTHCARE · Cap: $1.26T
PACS
PACS Group, Inc.
$49.60
-1.20%
HEALTHCARE · Cap: $7.77B
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 1458% more annual revenue ($86.46B vs $5.55B). LLY leads profitability with a 31.9% profit margin vs 4.8%. PACS appears more attractively valued with a PEG of 1.21. LLY earns a higher WallStSmart Score of 74/100 (B).
LLY
Strong Buy74
out of 100
Grade: B
PACS
Buy58
out of 100
Grade: C
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 68 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 53.7%
Revenue surging 38.6% year-over-year
Generating 8.2B in free cash flow
Earnings expanding 51.6% YoY
Every $100 of equity generates 24 in profit
Areas to Watch
Elevated debt levels
Premium valuation, high expectations priced in
Trading at 30.0x book value
Moderate valuation
4.8% margin — thin
Distress zone — elevated risk
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 31.9% and operating margin at 53.7%. Revenue growth of 38.6% demonstrates continued momentum.
Bull Case : PACS
The strongest argument for PACS centers on EPS Growth, Return on Equity. PEG of 1.21 suggests the stock is reasonably priced for its growth.
Bear Case : LLY
The primary concerns for LLY are Debt/Equity, P/E Ratio, Price/Book. A P/E of 46.0x leaves little room for execution misses.
Bear Case : PACS
The primary concerns for PACS are P/E Ratio, Profit Margin, Altman Z-Score. Debt-to-equity of 2.83 is elevated, increasing financial risk. Thin 4.8% margins leave little buffer for downturns.
Key Dynamics to Monitor
LLY profiles as a growth stock while PACS is a value play — different risk/reward profiles.
LLY carries more volatility with a beta of 0.45 — expect wider price swings.
LLY is growing revenue faster at 38.6% — sustainability is the question.
LLY generates stronger free cash flow (8.2B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (74/100 vs 58/100), backed by strong 31.9% margins and 38.6% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →PACS Group, Inc.
HEALTHCARE · MEDICAL CARE FACILITIES · USA
PACS Group, Inc. is a prominent technology solutions provider dedicated to improving operational efficiency across various sectors through innovative software and hardware systems. The company prioritizes research and development to leverage emerging technological trends and drive digital transformation initiatives. With a strong portfolio of strategic collaborations and a solid market presence, PACS Group is well-positioned for sustainable growth, making it an attractive investment proposition for institutional investors seeking to participate in the rapidly evolving technology landscape.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?